Cortechs.ai | Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai grows quantitative brain imaging operations in Europe

(San Diego, CA) May 26, 2016 – Cortechs.ai, the leading medical software innovator providing trusted solutions for quantitative brain analysis, is pleased to announce the acceleration of its international expansion to the European market to address the growing demand for quantitative imaging solutions and to support its existing customer base in Europe.

Cortechs.ai’ flagship solution, NeuroQuant®, received CE mark clearance in 2014, paving the way for many European customers to use Cortechs.ai’ fully automated quantitative brain imaging solutions in clinical practice. Cortechs.ai’ quantitative imaging solutions, NeuroQuant and PETQuant™ provide neurologists, radiologists, and clinical researchers with accurate and convenient tools to quantify the volumes of specific brain structures providing evidenced-based assessments of brain atrophy which could be caused by neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

In conjunction with the expansion into Europe, Cortechs.ai has hired Peter Segers, MSc, to head the European team. Mr. Segers joins the company with over 18 years of market and business development experience in medical devices, with senior roles at Lightpoint Medical, Nucletron and BMEYE, as well as, Philips Medical Systems. He brings a wealth of expertise in building global enterprise relationships and has an extensive knowledge of medical imaging market. Mr. Segers is based out of Amsterdam.

“Our international expansion is a critical step in providing continuing access and support of Cortechs.ai’ proven and reliable quantitative volumetric analysis solutions,” said Guri Stark, CEO of Cortechs.ai. “NeuroQuant has experienced impressive acceptance and success in prominent clinical institutions in the US and we are excited to see the demand and growth in Europe as we expand our solutions and launch our new Multiple Sclerosis products later this summer.”

For more information about Cortechs.ai brain imaging analysis solutions, please visit Stand D40 at the 2nd Congress of the European Academy of Neurology (EAN) taking place May 28-31 in Copenhagen.

PETQuant is available for research use only.

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis solutions provide neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

 

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

09/16/2025

OnQ Prostate for Focal Therapy

Read how OnQ Prostate supports focal therapy by personalizing prostate cancer care for patients while minimizing the risks associated with it.

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.
Scroll to Top